DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline
TMC207 for multidrug-resistant tuberculosis. N Engl J Med,
2009, 360:2397–2405.
Dooley K, Flexner C, Hackman J, et al. Repeated administration
of high-dose intermittent rifapentine reduces rifapentine and
moxifloxacin plasma concentrations. Antimicrob Agents
Chemother, 2008, 52:4037–4042.
Gatti G, Hossein J, Malena M, Cruciani M, Bassetti M.
Penetration of dapsone into cerebrospinal fluid of patients with
AIDS. J Antimicrob Chemother, 1997, 40:113–115.
Ginsburg AS, Woolwine SC, Hooper N, et al. The rapid development
of fluoroquinolone resistance in M. tuberculosis. N Engl
J Med, 2003, 349:1977–1978.
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official
ATS/IDSA statement: Diagnosis, treatment, and prevention of
nontuberculous mycobacterial diseases. Am J Respir Crit Care
Med, 2007, 175:367–416.
Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent
Mycobacterium tuberculosis killing and prevention of resistance
by rifampin. Antimicrob Agents Chemother, 2007a,
51:3781–3788.
Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin
dose that suppresses drug resistance in Mycobacterium tuberculosis,
by use of an in vitro pharmacodynamic infection model
and mathematical modeling. J Infect Dis, 2004, 190:1642–1651.
Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity
and resistance emergence: integrating pharmacodynamics
and pharmacogenomics to predict efficacy in different ethnic
populations. Antimicrob Agents Chemother, 2007b, 51:
2329–2336.
Gumbo T, Louie A, Liu W, et al. Isoniazid’s bactericidal activity
ceases because of the emergence of resistance, not depletion
of Mycobacterium tuberculosis in the log phase of growth.
J Infect Dis, 2007c, 195:194–201.
Gumbo T, Siyambalapitiyage Dona CS, Meek C, Leff R.
Pharmacokinetics-pharmacodynamics of pyrazinamide in a
novel in vitro model of tuberculosis for sterilizing effect: a paradigm
for faster assessment of a new antituberculosis drugs.
Antimicrob Agents Chemother, 2009, 53:3197–3204.
Hazbón MH, Brimacombe M, Bobadilla del Valle M, et al.
Population genetics study of isoniazid resistance mutations
and evolution of multidrug-resistant Mycobacterium tuberculosis.
Antimicrob Agents Chemother, 2006, 50:2640–2649.
Heifets LB. Antituberculosis drugs: Antimicrobial activity in
vitro. In: Drug Susceptibility in the Chemotherapy of
Mycobacterial Infections (Heifets LB, ed.), CRC Press, Boca
Raton, FL, 1991, pp.13–57.
Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial
spectrum of a diarylquinoline ATP synthase
inhibitor. Antimicrob Agents Chemother, 2007, 51:4202–4204.
Jayaram R, Shandil RK, Gaonkar S, et al. Isoniazid pharmacokinetics-pharmacodynamics
in an aerosol infection model of tuberculosis.
Antimicrob Agents Chemother, 2004, 48:2951–2957.
Ji B, Perani EG, Petinom C, Grosset JH. Bactericidal activities
of combinations of new drugs against Mycobacterium leprae in
nude mice. Antimicrob Agents Chemother, 1996, 40:393–399.
Johnson JL, Hadad DJ, Boom WH, et al. Early and extended
early bactericidal activity of levofloxacin, gatifloxacin and
moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung
Dis, 2006, 10:605–612.
Kasperbauer SH, Daley CL. Diagnosis and treatment of infections
due to Mycobacterium avium complex. Semin Respir Crit
Care Med, 2008, 29:569–576.
Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should
we use N-acetyltransferase type 2 genotyping to personalize
isoniazid doses? Antimicrob Agents Chemother, 2005,
49:1733–1738.
Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target
subunit c of mycobacterial ATP synthase. Nat Chem Biol,
2007, 3:323–324.
Kroger A, Pannikar V, Htoon MT, et al. International open trial
of uniform multi-drug therapy regimen for 6 months for all
types of leprosy patients: Rationale, design and preliminary
results. Trop Med Int Health, 2008, 13:594–602.
Langdon G, Wilkins J, McFadyen L, et al. U. S. Population pharmacokinetics
of rifapentine and its primary desacetyl metabolite
in South African tuberculosis patients. Antimicrob Agents
Chemother, 2005, 49:4429–4436.
Larsen MH, Vilcheze C, Kremer L, et al. Overexpression of
inhA, but not kasA, confers resistance to isoniazid and
ethionamide in Mycobacterium smegmatis, M. bovis BCG
and M. tuberculosis. Mol Microbiol, 2002, 46:453–466.
Levis WR, Ernst JD. Mycobacterium leprae (Leprosy, Hansen’s
disease). In: Mandell, Douglas, and Bennett’s Principles and
Practices of Infectious Diseases (Mandell GL, Bennett JE,
Dolin R, eds.), Elsevier Churchill Livingstone, Philadelphia,
2005, pp. 2886–2896.
Lewis M. Antimycobacterial agents: Ethambutol. In: Antimicrobial
Therapy and Vaccines (Yu LV, Merigan TC, Barriere SL, eds.),
Williams & Wilkins, Baltimore, 1999, pp. 643–650.
Lounis N, Veziris N, Chauffour A, et al. Combinations of
R207910 with drugs used to treat multidrug-resistant tuberculosis
have the potential to shorten treatment duration.
Antimicrob Agents Chemother, 2006, 50:3543–3547.
Malone RS, Fish DN, Spiegel DM, et al. The effect of hemodialysis
on cycloserine, ethionamide, para-aminosalicylate, and
clofazimine. Chest, 1999a, 116:984–990.
Malone RS, Fish DN, Spiegel DM, et al. The effect of hemodialysis
on isoniazid, rifampin, pyrazinamide, and ethambutol. Am
J Respir Crit Care Med, 1999b, 159:1580–1584.
Mathys V, Wintjens R, Lefevre P, et al. Molecular genetics of
para-aminosalicylic acid (PAS) resistance in clinical isolates
and spontaneous mutants of Mycobacterium tuberculosis.
Antimicrob Agents Chemother, 2009, 53:2100–2109.
Morris RP, Nguyen L, Gatfield J, et al. Ancestral antibiotic resistance
in Mycobacterium tuberculosis. Proc Natl Acad Sci USA,
2005, 102:12200–12205.
Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled
trials of rifabutin prophylaxis against Mycobacterium avium
complex infection in AIDS. N Engl J Med, 1993, 329:828–833.
Nix DE, Adam RD, Auclair B, et al. Pharmacokinetics and relative
bioavailability of clofazimine in relation to food, orange
juice and antacid. Tuberculosis (Edinb), 2004, 84:365–373.
Nouvel LX, Kassa-Kelembho E, Dos Vultos T, et al. Multidrugresistant
Mycobacterium tuberculosis, Bangui, Central African
Republic. Emerg Infect Dis, 2006, 12:1454–1456.
Okamoto S, Tamaru A, Nakajima C, et al. Loss of a conserved
7-methylguanosine modification in 16S rRNA confers lowlevel
streptomycin resistance in bacteria. Mol Microbiol, 2007,
63:1096–1106.
1569
CHAPTER 56
CHEMOTHERAPY OF TUBERCULOSIS, MYCOBACTERIUM AVIUM COMPLEX DISEASE, AND LEPROSY